Prab: CSV import

2025-03-17T12:30:37Z

CSV import

← Older revision		Revision as of 12:30, 17 March 2025
Line 33:		Line 33:
	[[Category:Endocrinology]]		[[Category:Endocrinology]]
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T19:34:39Z

CSV import

← Older revision		Revision as of 19:34, 10 February 2025
Line 32:		Line 32:
	[[Category:Metabolism]]		[[Category:Metabolism]]
	[[Category:Endocrinology]]		[[Category:Endocrinology]]
			{{No image}}

Prab: CSV import

2024-12-10T21:24:56Z

CSV import

New page

{{DISPLAYTITLE:Small Heterodimer Partner}}

'''Small Heterodimer Partner (SHP)''', also known as '''NR0B2''', is an atypical orphan nuclear receptor that plays a crucial role in the regulation of various metabolic pathways, including bile acid synthesis, glucose metabolism, and lipid homeostasis. Unlike classical nuclear receptors, SHP lacks a DNA-binding domain and functions primarily by interacting with other nuclear receptors to modulate their activity.

==Structure and Function==
SHP is a member of the nuclear receptor superfamily, specifically classified as an orphan receptor due to the absence of a known endogenous ligand. It is encoded by the '''NR0B2''' gene located on chromosome 1 in humans. The protein consists of a ligand-binding domain but lacks the typical DNA-binding domain found in other nuclear receptors.

SHP exerts its effects by forming heterodimers with other nuclear receptors, such as the [[Liver X Receptor]] (LXR), [[Farnesoid X Receptor]] (FXR), and [[Retinoid X Receptor]] (RXR). Through these interactions, SHP can repress the transcriptional activity of its partner receptors, thereby influencing the expression of target genes involved in metabolic processes.

==Role in Metabolism==
SHP is a critical regulator of bile acid homeostasis. It is induced by [[Farnesoid X Receptor|FXR]] in response to elevated bile acid levels. Once activated, SHP inhibits the expression of [[Cholesterol 7 alpha-hydroxylase]] (CYP7A1), the rate-limiting enzyme in bile acid synthesis, thus reducing bile acid production.

In addition to its role in bile acid metabolism, SHP is involved in glucose and lipid metabolism. It has been shown to influence insulin sensitivity and glucose homeostasis by modulating the expression of genes involved in gluconeogenesis and lipogenesis.

==Clinical Significance==
Dysregulation of SHP expression or function has been implicated in various metabolic disorders, including [[Non-alcoholic Fatty Liver Disease]] (NAFLD), [[Type 2 Diabetes Mellitus]], and [[Obesity]]. Understanding the mechanisms by which SHP regulates metabolic pathways may provide insights into potential therapeutic targets for these conditions.

==Research Directions==
Current research is focused on elucidating the precise molecular mechanisms by which SHP interacts with other nuclear receptors and identifying potential ligands or modulators that can influence its activity. Additionally, studies are exploring the role of SHP in the context of metabolic diseases and its potential as a therapeutic target.

==Also see==
* [[Nuclear Receptor]]
* [[Farnesoid X Receptor]]
* [[Liver X Receptor]]
* [[Cholesterol 7 alpha-hydroxylase]]
* [[Non-alcoholic Fatty Liver Disease]]

{{Nuclear Receptors}}
{{Metabolism}}

[[Category:Nuclear Receptors]]
[[Category:Metabolism]]
[[Category:Endocrinology]]

Small heterodimer partner - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import